Details of the Drug

General Information of Drug (ID: DMO9HWU)

Drug Name

D-7193

Synonyms

D-7042

Indication

Disease Entry	ICD 11	Status	REF
Immune System disease	4A01-4B41	Discontinued in Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Integrin alpha-M (ITGAM)	OTAG6HWU	ITAM_HUMAN	Gene/Protein Processing	[3]
Interleukin-2 receptor subunit alpha (IL2RA)	OT0MWCHG	IL2RA_HUMAN	Gene/Protein Processing	[3]
L-selectin (SELL)	OT6RAJZR	LYAM1_HUMAN	Gene/Protein Processing	[3]
Receptor-type tyrosine-protein phosphatase C (PTPRC)	OT6KOR77	PTPRC_HUMAN	Gene/Protein Processing	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007192)
2	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
3	The new oral immunomodulating drug DiNAC induces brachial artery vasodilatation at rest and during hyperemia in hypercholesterolemic subjects, likely by a nitric oxide-dependent mechanism. Atherosclerosis. 2008 Jan;196(1):275-282. doi: 10.1016/j.atherosclerosis.2006.10.031. Epub 2006 Dec 8.